Castle Biosciences (CSTL) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Castle Biosciences to Share Data Reinforcing the Clinical Value of Its Dermatologic Portfolio of Gene Expression Profile Tests at the 22nd Annual Winter Clinical Dermatology Conference - Hawaii
BusinesswireFeb 12 16:30 ET
Castle Biosciences (CSTL) Upgraded to Buy: Here's Why
Zacks Feb 12 11:25 ET
Insider Sale: Director at $CSTL Sells 1,425 Shares
Quiver QuantitativeFeb 7 16:17 ET
DNLI Reports Upbeat Longer-Term Data From Hunter Syndrome Study
Zacks Feb 7 09:05 ET
Press Release: Castle Biosciences to Release Fourth Quarter and Full-Year 2024 Financial Results and Host Conference Call on Thursday, Feb. 27, 2025
Dow JonesFeb 6 07:04 ET
Strong Week for Castle Biosciences (NASDAQ:CSTL) Shareholders Doesn't Alleviate Pain of Three-year Loss
Yahoo FinanceFeb 1 07:17 ET

Comments

Stock_Drift

Oct 20, 2024 04:18

$Castle Biosciences (CSTL.US)$

Teddy123

Sep 29, 2024 21:15

New Data at ASTRO 2024 Shows Castle Biosciences’ DecisionDx®-SCC Test Provides More Precise Risk Stratification Than BWH Staging Alone to Guide Intensified Treatment for Immune Suppressed Patients w

$Castle Biosciences (CSTL.US)$
New Data at ASTRO 2024 Shows Castle Biosciences’ DecisionDx®-SCC Test Provides More Precise Risk Stratification Than BWH Staging Alone to Guide Intensified Treatment for Immune Suppressed Patients with High-Risk Cutaneous Squamous Cell Carcinoma | CSTL Stock News

1

Trytosaveabit

May 29, 2024 15:33

Nice!

$Castle Biosciences (CSTL.US)$ New Publication Shows DecisionDx®-SCC Identifies High-Risk Squamous Cell Carcinoma Patients Who Are Likely to Benefit from Adjuvant Radiation Therapy and Those Who Can Consider Deferring Treatment Based on Biological Risk of Metastasis 1 MINUTE AGO, 4:30 PM EDT VIA BUSINESSWIRE

2

Moomoo AI

Mar 17, 2024 08:44

Despite impressive revenue growth, the high P/S ratio and average growth expectations make the share price seem overvalued. Predicted future revenues may not support this positive sentiment, risking shareholders' investments and potential investors paying a premium.

More Unpleasant Surprises Could Be In Store For Castle Biosciences, Inc.'s (NASDAQ:CSTL) Shares After Tumbling 25%

1

Moomoo AI

Mar 3, 2024 07:37

Castle Biosciences' progress over the last year is impressive, and it is well-positioned to raise more cash for growth with minimal dilution or borrowing. Its cash burn situation is not risky due to revenue growth and cash burn reduction.

Here's Why We're Not At All Concerned With Castle Biosciences' (NASDAQ:CSTL) Cash Burn Situation

CSTL Castle Biosciences

Trade Overview

Capital Trend

News

Comments

Trending Stocks